

CERTIFICATE OF ANALYSIS

DRAXIMAGE MAA kit, CND (10 vials/kit) 2.5 mg of Stannous Albumin Macro Aggregate / vial

# Certificate:	2022FE28-1			
Batch Number:	1K139	Manufacturing Date:	2022JA17	
Lot Number (FP):	1K139	Expiry Date:	2024 - JA	
Product Number:	500150	Specification Number and Version:	500150_v15	
Standard of Testing:	House, USP ¹	Date of Release: (Date with QA Initials)	MMN 2022 FE 230	

		Tests on the Lyophilized product	
Test Description	Analytical Method	Specifications	Results
Description	10019	A white freeze-dried plug or powder, clean and free of foreign matter. The flip-off cap is blue.	Conforms
Resuspendability	10079	A white suspension which may separate on standing.	Conforms
рН	10005	5.2 – 6.0	5.5
Loss on Drying	10021	≤ 5%	2%
Particle Density	10088	3 - 8 x 10 ⁶ aggregated albumin particles in each vial	5 x 10E06 particles/vial
Particle Size	10080	Particle Size < 10 μm: ≤ 10%	8%
		Particle Size ≥ 10 µm - ≤ 70 µm: ≥ 90%	92%
		Particle Size > 100 μm: ≤ 0.2%	<0.1%
		Particle Size > 150 μm: none	None
MAA Identification	10000	A blue color develops.	Conforms
SnCl₂.2H₂O Assay	10039	≥ 0.06 mg/vial	0.11 mg/vial
Total Tin Assay	10040	≤ 0.12 mg of SnCl₂•2H₂O/vial	0.09 mg/vial
Stannous Albumin Macro Aggregated Complex	10082	2.2 – 3.0 mg/vial	2.5 mg/vial
Human Serum Albumin	10068	3.5 – 6.5 mg/vial (or alternative method 10089)	5.4 mg/vial
Sodium Chloride	10084	0.96 – 1.44 mg/vial	1.34 mg/vial

0 PR 142623 MMN 2022 FE28

3 MT 2022 FE 28

A Jubilant Pharma Company



Radiopharmaceuticals Division Jubilant DraxImage Inc., dba Jubilant Radiopharma 16 751 TransCanada Highway Kirkland, Québec, Canada H9H 4J4 Tel.: +1 888 633 5343

Fax: +1 866 431 4288

http://www.jubilantradiopharma.com



CERTIFICATE OF ANALYSIS

DRAXIMAGE MAA kit, CND (10 vials/kit) 2.5 mg of Stannous Albumin Macro Aggregate / vial

# Certificate:	2022FE28-1		
Batch Number:	1K139	Manufacturing Date:	2022JA17
Lot Number (FP):	1K139	Expiry Date:	2024 - JA
Product Number:	500150	Specification Number and Version:	500150_v15
Standard of Testing:	House, USP ¹	Date of Release: (Date with QA Initials)	MAN 20 82 FE 23 0

Tests on the Lyophilized product				
Test Description	Analytical Method	Specifications	Results	
Residual Solvents ¹	USP<467>	Meets USP requirements (No Test Required)	Conforms	
Sterility ^{1,2}	10007	Sterile	Conforms	
Bacterial Endotoxins	10008	≤ 16.5 EU/vial	8.2 EU/vial 🛞	

	Te	ests on the Reconstituted product	
Test Description	Analytical Method	Specifications	Results
Radiochemical Purity	10043	Not less than 90% of the total radioactivity is found as aggregated albumin at the point of application, at 15 – 30 minutes post labeling.	100%
		Not less than 90% of the total radioactivity is found as aggregated albumin at the point of application, at least 8 hours post labeling.	100%
Centrifugation Procedure	10087	Not more than 10% of the total radioactivity is found in the supernatant liquid, at 15 – 30 minutes post labeling.	3%
		Not more than 10% of the total radioactivity is found in the supernatant liquid, at least 8 hours post labeling.	2%
	10044	In not less than 2 of 3 animals, at 15 – 30 minutes post labeling, not less than 80% of the radioactivity is found in the lungs of the animal at 15 minutes post injection.	Animal 1: 89%
			Animal 2: 98%
			Animal 3: 98%
Biological Distribution		In not less than 2 of 3 animals, at 15 – 30 minutes post labeling, not more than a total of 5% of the radioactivity is found in the liver of the animal at 15 minutes post injection.	Animal 1: 1%
			Animal 2: 1%
			Animal 3: 1%
		In not less than 2 of 3 animals, at 15 – 30 minutes post	Animal 1: 1%
		labeling, not more than 5% of the radioactivity is found in	Animal 2: 1%
		the kidneys of the animal at 15 minutes post injection.	Animal 3: 1%

A Jubilant Pharma Company



Radiopharmaceuticals Division UPR 14 26 23 TON 2027 FE 28 Jubilant DraxImage Inc., dba Jubilant Radiopharma

16 751 TransCanada Highway

Kirkland, Québec, Canada H9H 4J4

Tel.: +1 888 633 5343 Fax: +1 866 431 4288

http://www.jubilantradiopharma.com

MT 2022 FE28



CERTIFICATE OF ANALYSIS

DRAXIMAGE MAA kit, CND (10 vials/kit) 2.5 mg of Stannous Albumin Macro Aggregate / vial

# Certificate:	2022FE28-1		
Batch Number:	1K139	Manufacturing Date:	2022JA17
Lot Number (FP):	1K139	Expiry Date:	2024 - JA
Product Number:	500150	Specification Number and Version:	500150_v15
Standard of Testing:	House, USP ¹	Date of Release: (Date with QA Initials)	MIN 20 22 FE 23 (1)

Tests on the Reconstituted product				
Test Description	Analytical Method	<u>Specifications</u>	Results	
Biological Distribution	10044	In not less than 2 of 3 animals, at 8 -24 hours post labeling, not less than 80% of the radioactivity is found in the lungs of the animal at 15 minutes post injection.	Animal 1: 99% Animal 2: 93% Animal 3: 98%	
		In not less than 2 of 3 animals, at 8 - 24 hours post labeling, not more than a total of 5% of the radioactivity is found in the liver of the animal at 15 minutes post	Animal 1: 1% Animal 2: 1%	
		injection.	Animal 3: 1%	
		In not less than 2 of 3 animals, at 8 – 24 hours post labeling, not more than 5% of the radioactivity is found in	Animal 1: 1%	
			Animal 2: 1%	
		the kidneys of the animal at 15 minutes post injection.	Animal 3: 1%	

²Outside testing

This batch of product has been tested by Jubilant DraxImage Quality Control Laboratory under Canadian Establishment License Number 101869-A and complies with the specification requirements.

MUSTAPHA TOLLABI QC Sr. Supervisor Verified by:

Name and Title

M. Tollali

Signature

Date

622 FE28

FAIZA MINDONI AA ASSOCIATE F. Minound Approved by:

Name and Title

2092 FE28

Signature

Date

A Jubilant Pharma Company

OURVALUES

Radiopharmaceuticals Division Jubilant DraxImage Inc., dba Jubilant Radiopharma 16 751 TransCanada Highway Kirkland, Québec, Canada H9H 4J4 Tel.: +1 888 633 5343

Fax: +1 866 431 4288

1 PR 142623 MAN 2022 FE 28

http://www.jubilantradiopharma.com

MT 2022 FE28